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http://dx.doi.org/10.1016/j.ccr.2013.11.011SUMMARYIn hepatocellular carcinoma (HCC), biomarkers for prediction of prognosis and response to immunotherapy
such as interferon-a (IFN-a) would be very useful in the clinic. We found that expression of retinoic acid-
inducible gene-I (RIG-I), an IFN-stimulated gene, was significantly downregulated in human HCC tissues. Pa-
tients with low RIG-I expression had shorter survival and poorer response to IFN-a therapy, suggesting that
RIG-I is a useful prognosis and IFN-a response predictor for HCC patients. Mechanistically, RIG-I enhances
IFN-a response by amplifying IFN-a effector signaling via strengthening STAT1 activation. Furthermore, we
found that RIG-I deficiency promotes HCC carcinogenesis and that hepatic RIG-I expression is lower in men
than in women. RIG-I may therefore be a tumor suppressor in HCC and contribute to HCC gender disparity.INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide and is among the leading causes of can-
cer-related death, especially in China (El-Serag, 2011). Until
now, surgery has remained the most effective treatment with
curative potential, but only 30%–40% of HCC patients are diag-Significance
Analysis of interferon-stimulated gene (ISG) expression in h
inducible gene-I (RIG-I) expression is significantly downregul
(IFN-a) effector signaling and therapeutic response in HCC. Tog
low RIG-I expression had shorter survival and poorer response
tissue may be useful as an HCC prognosis marker and in ident
may contribute to HCC gender disparity, as its expression in liv
deficiency also promotes HCC carcinogenesis in mice.nosed at early stages and amenable to potentially curative surgi-
cal therapy. However, patients who have undergone radical
tumor resection have a high rate of relapse, and a 5 year survival
rate is only about 60% in well-selected patients (Llovet et al.,
2003). Systemic and targeted therapies, such as transcatheter
arterial chemoembolization, sorafenib, and interferon-alpha
(IFN-a), may provide clinical benefit in prolonging patients’epatocellular carcinoma (HCC) revealed that retinoic acid-
ated in HCC. RIG-I was also found to promote interferon-a
ether with clinical data that patients whose tumors exhibited
to IFN-a therapy, we propose that RIG-I expression in HCC
ifying good responders to IFN-a therapy. Furthermore, RIG-I
er tissues is significantly lower in men than in women. RIG-I
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RIG-I in HCC Carcinogenesis and IFN-a Therapysurvival, but the difficulty in identifying patients who might
respond well often makes these targeted adjuvant therapies
less effective (Finn, 2008; Melief, 2008; Zou, 2005; Sun et al.,
2006; Lo et al., 2007; Clavien, 2007; Llovet et al., 2008). For
IFN-a, a promising but incompletely understood anticancer
agent, clinical trials have demonstrated benefit in both hemato-
logical and solid tumors, although the effectiveness is somewhat
modest in HCC (Sun et al., 2006; Lo et al., 2007; Clavien, 2007).
IFN-a therapy has been suggested to be effective in a subgroup
of HCC patients, and it has been suggested that patients with
single-nodule tumor and ablation therapy or low miR-26a
expression in HCC tend to respond better to adjuvant IFN-a
treatment (Ji et al., 2009; Shen et al., 2010). Thus, identification
of molecular biomarkers that can identify HCC patients sensitive
to IFN-a therapy would be very helpful in the clinic.
IFN-a has various biological properties, including antiviral
response, immune modulation, and antiproliferative activity
(Taniguchi and Takaoka, 2001). It has therefore been widely
used for the treatment of viral infections and cancer. The binding
of IFN-a to its cell-surface receptors activates the downstream
Janus kinase (JAK) signal transducer and the activator of tran-
scription (STAT) signaling cascade, which then induces the
transcription of a set of genes, namely IFN-stimulated genes
(ISGs). Currently, about 300 ISGs have been identified through
oligonucleotide microarray studies, and these ISGs are respon-
sible for diverse biological functions of IFN-a, including its anti-
tumor activity (Platanias, 2005; Chawla-Sarkar et al., 2003).
The functions of ISGs in the regulation of infection and cancer,
including HCC, and how they might modulate responses to
IFN-a therapy are still not well understood.
RIG-I is well established to be one of the critical sensors
for host recognition of RNA virus infection and subsequent
induction of type I IFN. It contains a C-terminal helicase domain
to recognize cytoplasmic viral RNA such as that of influenza virus
and two N-terminal tandem caspase-recruiting domains
(CARDs) to activate downstream signaling and induce type I
IFN production (Takeuchi and Akira, 2010; Luo et al., 2011;
Kowalinski et al., 2011; Jiang et al., 2011a; Chen et al., 2013b).
As one of the ISGs, RIG-I expression is markedly induced
upon IFN-a stimulation, but the roles of RIG-I in IFN-a responses
are still unknown. Here we focused on the roles of RIG-I in the
control of HCC carcinogenesis and progression, especially its
role and the underlying mechanism in IFN-a therapeutic
response of HCC patients.
HCC occursmainly in men, one of the key andmost interesting
features of HCCcarcinogenesis (El-Serag andRudolph, 2007). In
a diethylnitrosamine (DEN)-induced HCC mouse model, it was
demonstrated that male mice were more susceptible as a result
of the enhanced production of proinflammatory cytokines, such
as interleukin-6 (IL-6) (Naugler et al., 2007; Park et al., 2010).
Other factors, such as sex hormones, menstruation, pregnancy,
oral contraceptive usage, and endocrinology disorders have also
been proposed to be associated with HCC carcinogenesis (Buch
et al., 2008; Ruggieri et al., 2010; Vana et al., 1977). Furthermore,
female HCC patients tend to have longer survival times than
men, suggesting that differentially expressed molecules be-
tween genders or gender-related factors might be associated
with both HCC carcinogenesis and prognosis (Ng et al., 1995;
Dohmen et al., 2003). Understanding the mechanism respon-50 Cancer Cell 25, 49–63, January 13, 2014 ª2014 Elsevier Inc.sible for the higher incidence and poorer prognosis of HCC
in men would also be important in tackling this devastating
disease.
RESULTS
Characteristics of HCC Patients Used in This Study
We obtained snap-frozen or paraffin-embedded HCC tissues
and surrounding nontumor hepatic tissues from 443 HCC
patients who had undergone radical resection between 1999
and 2006. This study involved four independent cohorts of
HCC patients. Cohorts 1 and 2 included 152 and 140 HCC
patients, respectively, and RIG-I mRNA level was determined
in these cohorts using a quantitative RT-PCR (qRT-PCR) assay
because only RNA samples were available. The correlation of
RIG-I expression with gender and survival was analyzed in these
HCC cohorts. Cohorts 3 and 4 included 76 and 75 HCC patients,
respectively, and they were from two independent, prospective,
randomized, controlled trials of adjuvant IFN-a therapy for HCC
patients (Sun et al., 2006; Lo et al., 2007; Ji et al., 2009). In
cohorts 3 and 4, RIG-I protein level was determined using immu-
nohistochemistry tissue microarray, and its correlation with
gender and survival was analyzed. Furthermore, we evaluated
the correlation between RIG-I expression and IFN-a therapeutic
response in these patients.
Most of the HCCpatients in the four cohorts weremen (86.9%)
and carriers of hepatitis B virus (HBV) (90.7%), had liver cirrhosis
(61.4%), elevated serum a-fetoprotein (AFP) level (63.7%), and a
single tumor nodule at the time of resection (78.3%) (Table 1).
Clinical variables were similar in the four patient cohorts, with
the exception of age, liver cirrhosis, and tumor-node-metastasis
(TNM) stage. The patients in cohort 2 were relatively younger
than those in the other three cohorts; fewer patients in cohort 2
and more patients in cohort 4 had liver cirrhosis, and more
patients in cohort 4 had early-stage tumors.Moreover, in cohorts
3 and 4, 48.7% and 53.3% of the patients had received ‘‘inten-
tion-to-cure’’ adjuvant IFN-a therapy, respectively, which
improved overall survival (Sun et al., 2006; Lo et al., 2007; Ji
et al., 2009).
RIG-I Is the Most Significantly Decreased ISG in HCC
Because whether ISGs might modulate response to IFN-a
therapy in HCC is still not well studied, we performed a cDNA
microarray and focused on differentially expressed ISGs in
HCC tissues, as compared to those in matched nontumor liver
tissues (de Veer et al., 2001). The expression of ISGs in the
four male patients examined is shown in Figure S1A available
online. Among them, we found that RIG-I was the most signifi-
cantly decreased ISG in HCC tissues (Figure S1B; Table S1).
Furthermore, as compared to that in the matched nontumor liver
tissues of the HCC cohorts, RIG-I expression was significantly
decreased in HCC tissues of the patients in cohorts 1 and 2,
respectively, as detected by qRT-PCR for its mRNA level, and
in cohort 3, as detected by immunohistochemistry for its protein
level (Figures 1A and 1B; Figure S1C). We conclude that RIG-I
expression is significantly decreased in HCC.
We next investigated the underlying mechanism of RIG-I
decrease in HCC in four HCC tissues with markedly decreased
RIG-I expression (data not shown). First, we determined that
Table 1. Clinical Characteristics of HCC Patients
Variable
Cohort 1
(n = 152)
Cohort 2
(n = 140)
Cohort 3
(n = 76)
Cohort 4
(n = 75) p Value
Gender (%) 0.277
Female 18 (11.8) 15 (10.7) 15 (19.7) 10 (13.3)
Male 134 (88.2) 125 (89.3) 61 (80.3) 65 (86.7)
Age (years) <0.001
Median 48 42 52 50
Range 20–78 23–74 24–75 30–77
HBV (%) 0.167
Negative 19 (12.5) 7 (5.0) 8 (10.5) 7 (9.3)
Positive 133 (87.5) 133 (95.0) 68 (89.5) 68 (90.7)
Cirrhosis (%) <0.001
No 40 (26.3) 88 (62.9) 37 (48.7) 6 (8.0)
Yes 112 (73.7) 52 (37.1) 39 (51.3) 69 (92.0)
AFP (%) 0.063
Negative,
%20 ng/ml
65 (42.8) 40 (28.6) 31 (40.8) 25 (33.3)
Positive,
>20 ng/ml
87 (57.2) 100 (71.4) 45 (59.2) 50 (66.7)
Tumor size (%) 0.114
%3 cm 68 (44.7) 50 (35.7) 22 (28.9) 30 (40.0)
>3 cm 84 (55.3) 90 (64.3) 54 (71.1) 45 (60.0)
Tumor
number (%)
0.124
=1 111 (73.0) 110 (78.6) 61 (80.3) 65 (86.7)
>1 41 (27.0) 30 (21.4) 15 (19.7) 10 (13.3)
TNM stage (%) <0.001
I and II 69 (45.4) 68 (48.6) 40 (52.6) 58 (77.3)
III and IV 83 (54.6) 72 (51.4) 36 (47.4) 17 (22.7)
A p value < 0.05 was considered to indicate statistical significance. The
p values were calculated in SPSS 17.0 using c2 test, except for age,
which was calculated using one-way ANOVA.
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genome, as real-time PCR detected equal amounts of RIG-I
from equal amounts of genomic DNA extracted from HCC and
matched nontumor tissues (data not shown). Second, we
sequenced the RIG-I gene including both the coding and un-
translational regions from the same nontumor and HCC tissues
and found no mutation (data not shown). Third, in the two CpG
islands upstream of the RIG-I-coding region, DNA CpG was
hypomethylated in both HCC and nontumor samples by using
bisulfate sequencing (Figures S1D and S1E). DNA methylation
inhibitor 5-azacytidine treatment also had no effect on RIG-I
expression in HCC SMMC-7721 and BEL-7402 cells (data not
shown). Fourth, we performed chromatin immunoprecipitation
(ChIP) experiments and found that histone acetylation of the
RIG-I gene was not significantly altered in HCC as compared
to that in nontumor tissues. Histone deacetylase inhibitor tri-
chostatin A treatment also had no effect on RIG-I expression in
SMMC-7721 and BEL-7402 cells (data not shown). Fifth, as
methylation of histone H3 at Lys4 (H3K4) is linked to transcrip-
tional activation, whereas methylation of H3 at K9 or K27 and
of H4 at K20 is linked to transcriptional repression (Esteller,2008), we found that theRIG-I gene locus showed reduced levels
of H3K4me3 but increased levels of H3K9me3 and H3K27me3
in HCC as compared to that in nontumor tissues (Figures S1F
and S1G), and the level of H4K20me3 was not altered (data
not shown). Taken together, these data suggest that lower
RIG-I expression in HCC is at least in part mediated by deregu-
lated histone methylation at the RIG-I gene locus.
Association of RIG-I Expression in HCC Tissues with
HCC Progression
As RIG-I expression is significantly decreased in HCC, we further
evaluated the association of RIG-I expression in HCC with the
prognosis of HCC patients. Using themedian value as the cutoff,
we found that low RIG-I expression in HCC was significantly
correlated with the reduced disease-free survival and overall
survival of HCC patients in cohorts 1 and 2 and the control group
patients in cohorts 3 and 4 (Figures 1C–1E). Cox proportional
hazards regression analysis also determined that low RIG-I
expression in the tumor is an independent predictor for reduced
survival of HCC patients in the analyzed cohorts (Tables S2–S7).
Thus, the dichotomized value of RIG-I expression is an indepen-
dent predictor for prognosis of HCC patients. Additionally, it
should be noted that the cohorts of HCC patients we analyzed
were all Chinese patients with a high rate of chronic hepatitis B
(90.7%). In HBV-related HCC, low RIG-I expression in HCC
was also significantly correlated with poor prognosis of HCC in
cohorts 1 and 2 and the control group patients in cohorts 3
and 4 (Figures 1F–1H). In HCC derived from other diseases, it
was hard to analyze the data with sufficient statistical power
because of the limited number of patients. Future work is needed
to further confirm our conclusion in HCC patients related to other
liver diseases.
Association of RIG-I Expression in Human HCC Tissue
with IFN-a Therapeutic Response
Because RIG-I is a typical ISG, we next evaluated whether RIG-I
expression in the tumor was associated with the response of
patients to adjuvant IFN-a therapy. As shown in Figures 2A
and 2B, IFN-a treatment provided only limited benefit to the
overall survival of HCC patients in cohorts 3 and 4, whereas
HCC patients with high RIG-I expression in tumors had a signif-
icant improvement in overall survival after receiving adjuvant
IFN-a therapy, as compared to those in the control group. In
contrast, IFN-a therapy had little effect on overall survival of
HCC patients with low RIG-I expression in both cohorts. Repre-
sentative images of high and low RIG-I expression in HCC
tissues and the specificity of RIG-I staining in hepatocytes or
HCC cells are shown in Figures S2A–S2E. Cox proportional
hazards regression analysis also confirmed the enhanced effect
of IFN-a treatment on survival of HCC patients in cohorts 3 and 4
who had high RIG-I expression (Table 2). In both univariate and
multivariate analyses, IFN-a treatment was associated with
significant improvement in overall survival of HCC patients with
high RIG-I expression. A significant interaction was observed
between RIG-I expression and IFN-a therapy with respect to
the effect on survival (p = 0.026 for interaction in cohort 3; p =
0.037 for interaction in cohort 4). However, in patients with low
RIG-I expression, IFN-a treatment had little effect on overall
survival in cohorts 3 and 4 (Table S8). Thus, determination ofCancer Cell 25, 49–63, January 13, 2014 ª2014 Elsevier Inc. 51
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dent predictor for IFN-a treatment response.
It should be noted that these cohorts of HCC patients we
analyzed were all Chinese patients with a high rate of chronic
hepatitis B (Table1). In HBV-related HCC, it was also deter-
mined that only patients with high RIG-I expression in tumors
had a significant improvement in overall survival after receiving
adjuvant IFN-a therapy, as compared to those in the control
group in both cohorts 3 and 4 (Figures 2C and 2D). In HCC
derived from other diseases, it is also hard to analyze the
data with enough statistical power because of the limited
number of patients. The correlation between RIG-I level and
IFN-a therapy responsiveness of HCC patients therefore still
needs to be further evaluated in HCC patients as related to
other liver diseases, although our data suggested that HBV
replication seemed less relevant to RIG-I expression and
IFN-a response (Figures S2F–S2H). However, these results at
least suggest that determination of RIG-I expression may be
useful in the prediction of IFN-a response in HBV-related
HCC patients. Additionally, we also examined IFN-a receptor
(IFNAR) expression in cohort 3, and found that IFNAR expres-
sion was not significantly altered in HCC tissues as compared
to the matched nontumor liver tissues. IFNAR expression was
also poorly correlated with IFN-a response (data not shown),
thus excluding the possibility that IFN-a response of HCC
patients is directly due to the altered IFNAR expression in
HCC tissues. Moreover, we used the median RIG-I expression
value in cohorts 3 and 4, respectively, as the cutoff point for the
threshold of RIG-I expression in HCC, as median value is widely
accepted in survival analyses (Ji et al., 2009). The median RIG-I
staining values in cohorts 3 and 4 are 57.3 and 54.9, respec-
tively, which are similar. We also included additional HCC
tissues from 358 patients, and determined that the median
RIG-I staining value is 55.9, which is also similar to those in
cohorts 3 and 4. Furthermore, the median RIG-I mRNA expres-
sion level in HCC tissues of these 358 patients is 6.69, calcu-
lated as the cycle threshold value of b-actin minus that of RIG-I
(equal to the log2 transformed value). This median value is also
similar to those in cohorts 1 and 2, which are 6.75 and 6.64,
respectively. Hence, this value may roughly represent the
median RIG-I expression value in the HCC tissues of the
patients, and IFN-a therapy may be beneficial to the HCC
patients with RIG-I mRNA or protein expression higher than
this value. However, although this median value is determined
in a relatively larger cohort of HCC patients, this value is only
a ‘‘suggested’’ value for IFN-a therapy. Whether this value is
applicable still needs to be addressed in future large-scale pro-
spective IFN-a therapy trials.Figure 1. RIG-I Expression Is Decreased inHCC, and LowRIG-I Express
(A and B) RIG-I expression in HCC and nontumor liver tissues was analyzed in coh
in cohort 3, as determined by immunohistochemistry analysis for RIG-I protein l
represent the interquartile range, and the whiskers represent the 2.5th and 97.5t
(C–E) Shown are Kaplan-Meier survival curves of disease-free survival (upper) and
of cohorts 1 (C), 2 (D), and control group patients in cohorts 3 and 4 (E). The medi
test for significance.
(F–H) Shown are Kaplan-Meier survival curves of disease-free survival (upper) an
cutoff value and statistical analysis as in (C)–(E).
See also Figure S1 and Tables S1–S7.RIG-I Enhances Response to IFN-a Therapy in HCC
We went further to investigate the association of RIG-I expres-
sion with the response to IFN-a therapy in HCC experimental
models both in vitro and in vivo. In HCC cell lines SMMC-7721
and BEL-7402, IFN-a inhibited HCC cell growth in vitro, but the
inhibitory effect was reduced by RIG-I knockdown (Figure 3A).
IFN-a-induced apoptosis of HCC cells was also suppressed by
RIG-I knockdown (Figure 3B). These results were confirmed in
the human HCC-bearing mouse model SMMC-LTNM, which
was generated by transplanting histologically intact fresh human
HCC tissues to form subcutaneous transplantation tumors in
nude mice followed by continuous subcutaneous passaging
(Hou et al., 2011). In SMMC-LTNM, the inhibitory effect of
IFN-a was attenuated by intratumoral injection of cholesterol-
conjugated RIG-I siRNA (Figures 3C and 3D), as determined by
tumor size and serum AFP. Furthermore, we constructed RIG-I
stably knocked down and RIG-I stably overexpressed SMMC-
7721 cells and prepared HCC-bearing nude mice with different
RIG-I expressions. The inhibitory effect of IFN-a was also sig-
nificantly reduced in nude mice bearing RIG-I stably knocked
down SMMC-7721 tumors while enhanced in RIG-I stably over-
expressed SMMC-7721 tumors (Figures 3E–3H). Taken
together, these data suggest that higher RIG-I expression in
HCC enhances the antitumor effect of IFN-a.
Because the inhibitory effect of IFN-a is dependent on the
induced expression of ISGs (Chawla-Sarkar et al., 2003), four
ISGs associated with IFN-a-induced apoptosis were selected
to evaluate the effect of RIG-I on IFN-a-induced ISG expression,
including tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), promyelocytic leukemia (PML), X-linked inhibitor
of apoptosis protein-associated factor 1 (XAF1), and 2050A oli-
goadenylate synthetase 1 (OAS1) (Herzer et al., 2009). RIG-I
knockdown inhibited IFN-a-induced expression of these ISGs
in both HCC cell lines in vitro and SMMC-LTNM in vivo (Figures
4A and 4B). RIG-I deficiency also attenuated ISG induction in
both hepatocytes and DEN-induced murine HCC tissues upon
IFN-a stimulation (Figures 4C and 4D). Additionally, in RIG-I
stably overexpressed SMMC-7721 cells, IFN-a-induced ISG
expression was significantly enhanced (Figure 4E). These
data demonstrate that RIG-I functionally contributes to IFN-
a-induced expression of proapoptotic ISGs in HCC both
in vitro and in vivo.
RIG-I Strengthens IFN-JAK-STAT Effector Signaling by
Promoting STAT1 Activation through the Disruption of
SHP1-STAT1 Interaction
The activation of the intracellular JAK-STAT pathway mediates
the inductionof ISGexpressionupon IFN-a stimulation (Taniguchiion Is Significantly Correlatedwith Poorer Prognosis of HCCPatients
orts 1 and 2, as determined by qRT-PCR analysis for RIG-ImRNA level (A), and
evel (B). The horizontal lines in the box plots represent the median, the boxes
h percentiles. The p values shown were calculated using Student’s t test.
overall survival (lower) based on dichotomized RIG-I expression in HCC tissues
an level of RIG-I expression in each panel was used as the cutoff, with log-rank
d overall survival (lower) of HBV-related HCC patients in (C)–(E), with the same
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Table 2. Univariate and Multivariate Analysis of Factors
Associated with Overall Survival of HCC Patients with High RIG-I
Expression in Cohorts 3 and 4
Clinical Variables
High RIG-I in
Cohort 3 (n = 38)
High RIG-I in
Cohort 4 (n = 38)
Hazard Ratio
(95% CI)
p
Value
Hazard Ratio
(95% CI)
p
Value
Univariate analysis
IFN-a versus control 0.2 (0–0.9) 0.034 0.2 (0.1–0.9) 0.040
Gender
(male versus female)
2.5 (0.5–11.6) 0.256 1.0 (0.1–8.3) 0.973
Age (>50 versus
%50 years)
31 (0.1–1510) 0.277 0.5 (0.1–1.8) 0.285
HBV (positive
versus negative)
0.3 (0.1–1.6) 0.163 27 (0–5,232) 0.394
Cirrhosis
(yes versus no)
2.5 (0.6–9.5) 0.194 25 (0–1,448) 0.469
AFP (R500 versus
<500 ng/ml)
0.4 (0–3.1) 0.372 0.4 (0–2.9) 0.342
Tumor size (>3 cm
versus%3 cm)
0.9 (0.2–3.1) 0.832 1.9 (0.5–7.2) 0.327
Tumor number
(>1 versus 1)
1.7 (0.8–3.4) 0.305 2.1 (0.4–10.2) 0.353
Tumor capsule
(no versus yes)
2.4 (0.5–11.4) 0.262 0.7 (0.2–2.9) 0.649
Venous infiltration
(yes versus no)
1.8 (0.5–6.2) 0.351 1.3 (0.3–6.1) 0.766
TNM stage
(>II versus I/II)
2.8 (0.7–10.8) 0.136 1.9 (0.4–9.1) 0.430
Histological grade
(>II versus I/II)
0.5 (0.1–1.7) 0.250 1.1 (0.2–5.1) 0.947
Multivariate analysis
IFN-a versus control 0.2 (0–0.9) 0.038 0.2 (0.1–0.9) 0.036
Gender
(male versus female)
1.1 (0.2–6.0) 0.941 1.9 (0.2–15.3) 0.562
TNM stage
(>II versus I/II)
3.2 (0.8–13.4) 0.113 1.8 (0.4–8.8) 0.475
Analysis was conducted on HCC patients with high RIG-I expression in
cohorts 3 and 4. IFN-a versus control represents 20 versus 18 patients
in cohort 3 and 21 versus 17 in cohort 4. Hazard ratios (95% confidence
interval; CI) and p values were calculated using univariate or multivariate
Cox proportional hazards regression in SPSS 17.0. A p value < 0.05 was
considered to indicate statistical significance.
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IFN-a-induced STAT1 activation and nuclear translocation (Fig-
ure 5A). In addition, IFN-a-induced STAT1 activation and nuclear
translocation were suppressed by RIG-I deficiency (Figure 5B).
These results suggest that RIG-I promotes the activation of IFN-Figure 2. Patients with Low RIG-I Expression in HCC Have Poorer Res
(A and B) Shown is the effect of adjuvant IFN-a therapy on the overall survival of
regardless of RIG-I expression, center panels show the effect in patients with hig
expression. The median level of RIG-I expression in each cohort was used as the
log-rank test for significance.
(C and D) Shown is the effect of adjuvant IFN-a therapy on the overall survival o
expression and statistical analysis as in (A) and (B).
See also Figure S2 and Table S8.JAK-STAT effector signaling in HCC cells. Furthermore, coimmu-
noprecipitation (co-IP) analysis revealed an inducible interaction
between endogenous STAT1 with RIG-I upon IFN-a stimulation
(Figure 5C). Additionally, in STAT1-silenced HCC cells, RIG-I
knockdown did not further suppress IFN-a-induced ISG expres-
sion (Figure S3). These data suggest that RIG-I may enhance the
antitumor effect of IFN-a by amplifying the IFN-JAK-STAT
effector pathway in HCC cells by promoting STAT1 activation.
To identify the mechanisms responsible for RIG-I to promote
STAT1 activation, we examined whether RIG-I worked as an
adaptor to enhance the association of STAT1 with upstream
kinases JAK1 and Tyk2. IFN-a-induced association of STAT1
with JAK1 and Tyk2 was not significantly influenced by RIG-I
deficiency (data not shown). We next focused on the negative
regulators of STAT1 and explored whether RIG-I disrupted
the negative regulation of STAT1 activation. By screening the
negative regulators of IFN-JAK-STAT signaling, including
SHP1, SHP2, SOCS1, SOCS3, PIAS1, and PIASY (Shuai and
Liu, 2003; David et al., 1995), we found that SHP1 most signifi-
cantly bound STAT1 upon IFN-a stimulation in liver tissues and
that SHP1-STAT1 interaction was significantly enhanced by
RIG-I deficiency (Figure 5D; data not shown). Furthermore, in
wild-type mouse liver tissue, RIG-I knockdown significantly sup-
pressed IFN-a-induced TRAIL expression, whereas in SHP1-
deficient mice, IFN-a-induced TRAIL expression was enhanced
and SHP1 deficiency abolished the RIG-I knockdown-mediated
suppression of IFN-a-induced TRAIL expression (Figure 5E).
Hence, RIG-I promotes STAT1 activation mainly through sup-
pressing the interaction and inhibition of STAT1 by SHP1.
To identify the molecular basis responsible for RIG-I-STAT1
interaction and SHP1-STAT1 interaction, we constructed
various fragments of RIG-I, SHP1, and STAT1 and found that
both the CARD domain of RIG-I and the SH2 domain of SHP1
could bind the SH2-transactivation (SH2-TA) domain of STAT1,
which is critical for STAT1 tyrosine phosphorylation and acti-
vation (Figures 5F and 5G). Furthermore, as SHP1 is a protein
tyrosine phosphatase, we performed a biochemical in vitro
dephosphorylation assay of STAT1 and found that the phos-
phorylated tyrosine in STAT1 could be dephosphorylated by
SHP1 but that the phosphatase activity of SHP1 could be signif-
icantly inhibited by RIG-I (Figure 5H). Together, these data led us
to the proposal that RIG-I may competitively bind the SH2-TA
domain of STAT1 so as to disrupt the binding of STAT1 with its
negative regulator SHP1. Impairment in SHP1-STAT1 interaction
prevents STAT1 dephosphorylation by SHP1 and provides a
basis for RIG-I-mediated promotion of STAT1 activation.RIG-I Deficiency Promotes HCC Carcinogenesis
As RIG-I expression is determined to be significantly decreased
in HCC and correlate with prognosis, we also examined whetherponse to IFN Therapy
HCC patients in cohorts 3 (A) and 4 (B). Left panels show the effect in patients
h RIG-I expression, and right panels show the effect in patients with low RIG-I
cutoff (mean DAB intensity 57.3 and 54.9 in cohorts 3 and 4, respectively), with
f HBV-related HCC patients in (A) and (B), with the same cutoff value of RIG-I
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Figure 3. RIG-I Contributes to the Antitumor Effect of IFN-a Both In Vitro and In Vivo
(A) Shown is cell growth determined by MTT assay in HCC cell lines SMMC-7721 (upper) and BEL-7402 (lower) transfected with control RNA or RIG-I siRNA and
then stimulated with 1,000 U/ml IFN-a for the indicated time.
(B) Shown is apoptosis determined by Annexin V-propidium iodide staining and flow cytometry in HCC cell lines treated as in (A).
(C) Human HCC-bearing nude mouse model SMMC-LTNM cells were intratumorally injected with saline buffer, cholesterol-conjugated control RNA, or RIG-I
siRNA as indicated. The expression of RIG-I and b-actin (internal control) was detected by western blot.
(D) Shown are tumor growth (upper) and serum AFP (lower) in SMMC-LTNM cells administered cholesterol-conjugated control RNA or RIG-I siRNA and treated
with IFN-a as indicated.
(legend continued on next page)
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We used the chemical carcinogen DEN-induced HCC mouse
model, which mimics human HCC development, including the
dependence on inflammation and gender disparity (Naugler
et al., 2007; Park et al., 2010; Grivennikov et al., 2010). RIG-I-
deficient mice used here are viable and fertile (Wang et al.,
2007; Zhang et al., 2008; Hou et al., 2009). Wild-type and RIG-
I-deficient mice were injected with a single dose of DEN on post-
natal day 15, and animals were sacrificed after 8 months to
examine HCC incidence (Figure 6A). RIG-I deficiency dramati-
cally increased the incidence, number, and size of liver tumors
(Figures 6B and 6C) and promoted HCC-related death in both
male and female mice (Figure 6D). Hence, these results suggest
that RIG-I deficiency promotes HCC carcinogenesis and that
RIG-I may act as a tumor suppressor. We did not find any spon-
taneous tumors in aged RIG-I-deficient mice, and H&E staining
of livers from aged RIG-I-deficient mice did not show any
obvious spontaneous hepatitis (Figure S4A). Hepatic macro-
phage Kupffer cells and the produced IL-6 have been shown to
play critical roles in HCC carcinogenesis (Naugler et al., 2007).
However, in our experiments, we found that DEN-induced IL-6
or tumor necrosis factor a production was not significantly influ-
enced by RIG-I deficiency (Figure S4B). Moreover, DEN-induced
IL-6 production is still higher in RIG-I-deficient male mice than in
females, as reported (Naugler et al., 2007), and was not reduced
by RIG-I deficiency (Figure S4B). Thus, it is likely that RIG-I defi-
ciency-promoted HCC carcinogenesis may be independent of
IL-6 production and nonparenchymal cells such as Kupffer cells.
However, although the potential roles of RIG-I in suppressing
HCC carcinogenesis have been suggested, more investigations
in the future are warranted to understand the tumor-suppressing
roles of RIG-I in HCC initiation and progression.
Association of Hepatic RIG-I Expression with Gender
Because RIG-I deficiency promotes HCC carcinogenesis and
one key feature of HCC epidemiology is gender disparity, we
further investigated whether RIG-I expression might contribute
to the HCC gender disparity in carcinogenesis. As shown in
Figure 6E, gender disparity in HCC carcinogenesis was reduced
by RIG-I deficiency, shown as the male versus female ratio of
HCC incidence, number, and size, suggesting that RIG-I contrib-
utes to HCC gender disparity. Furthermore, we examined
whether RIG-I expression in the liver was associated with
gender. Because adjacent nontumor liver tissue reflects the
precancerous state of human liver, we chose nontumor liver
tissues to detect RIG-I expression and its association with
HCC gender disparity in carcinogenesis. The clinical character-
istics of the female and male HCC patients in cohorts 1, 2, and
3 were similar (Table S9). We did not perform the analysis in
cohort 4 because the nontumor tissues in this cohort were not
available. In cohorts 1, 2, and 3, we found that RIG-I expression
in the nontumor liver tissues was significantly lower in men than
in women (Figure 6F; Figure S4C). Furthermore, normal human
liver tissues from 52 men and 50 women were collected, and(E and F) Shown is RIG-I expression in RIG-I stably knocked down (E) or overex
(G and H) Shown is tumor growth of nudemice bearing RIG-I stably knocked dow
Experimental data are shown as mean ± SD (n = 4) or photographs of one re
experiments. *p < 0.05; **p < 0.01.RIG-I expression in normal human liver was also found to be
significantly lower in men than in women (Figure 6G; Figures
S4D and S4E). Additionally, in mouse studies, we found that
RIG-I expression in normal mouse liver tissues was also signifi-
cantly lower in males than in females (Figure 6H). Moreover,
we found that the RIG-I gene locus showed an increased level
of H3K4me3 but decreased H3K9me3 and H3K27me3 in normal
human liver of women relative to men, and thus may contribute
to the higher hepatic RIG-I expression in women than in men
(Figure S4F). Taken together, our results suggest that lower
hepatic RIG-I expression in men may contribute to gender
disparity in HCC carcinogenesis.
DISCUSSION
It has been well accepted that RIG-I is an intracellular viral RNA
sensor and that its activation can initiate host innate immune
response, especially type I IFN production, to eliminate viral
infection (Takeuchi and Akira, 2010; Luo et al., 2011; Kowalinski
et al., 2011; Jiang et al., 2011a). However, recent investigations
of RIG-I in cancer also reported that RIG-I activation by its ligand
pppRNA could induce apoptosis in melanoma cells and ovarian
cancer cells (Besch et al., 2009; Ku¨bler et al., 2010), and inhibi-
tion of proliferation in acute myeloid leukemia cells could be
augmented by RIG-I expression upon retinoic acid treatment
(Jiang et al., 2011b). Consistent with these findings, our data
also suggest that RIG-I may be a tumor suppressor in HCC.
However, RIG-I expression may not be directly involved in the
apoptosis of HCC cells, as RIG-I knockdown poorly influences
the apoptosis induced by TRAIL or the chemotherapeutic drugs
doxorubicin and cisplatin (data not shown). We presume that
pppRNA-induced apoptosis is due to the activation of RIG-I,
especially the activation of RIG-I downstream signaling. The
induced RIG-I expression upon IFN-a stimulation may be a
positive feedback of IFN-a response to amplify IFN-a effector
signaling and ensure a longtime IFN-a efficacy, including IFN-
a-induced apoptosis. Hence, both RIG-I expression and activa-
tion may have tumor-suppressive effects in cancer cells.
The IFN-JAK-STAT pathway is known to be negatively regu-
lated by the phosphatase SHP1 (David et al., 1995; Shuai and
Liu, 2003). We found that RIG-I promotes STAT1 activation
through the disruption of SHP1-STAT1 interaction. Phosphoryla-
tion of the tyrosine at residue 701 located in the SH2-TA domain
is well established as playing critical roles in IFN-a-induced
STAT1 activation, dimerization, and transactivation of ISGs.
The STAT1 SH2-TA domain and phosphorylation of tyrosine
701 are tightly regulated by multiple mechanisms to ensure
proper response to IFN-a (Shuai and Liu, 2003), and RIG-I is
found to bind this SH2-TA domain to prevent the dephosphory-
lation or negative regulation of STAT1. Although RIG-I-promoted
STAT1 activation is abolished by SHP1 deficiency, we do not
exclude the possibility that RIG-I may also inhibit the interaction
of STAT1 with other molecules (especially negative regulators) or
that RIG-I may directly facilitate STAT1 activation. Furthermore,pressed (F) SMMC-7721 cells.
n (G) or overexpressed (H) SMMC-7721 tumors treated with IFN-a as indicated.
presentative experiment. Similar results were obtained in three independent
Cancer Cell 25, 49–63, January 13, 2014 ª2014 Elsevier Inc. 57
Figure 4. RIG-I Enhances IFN-a-Induced ISG Expression in HCC
(A) Shown is the induced ISG expression determined by qRT-PCR in HCC cell lines transfectedwithRIG-I siRNA and then stimulatedwith 1,000 U/ml IFN-a for the
indicated time.
(B) Shown is the induced ISGexpression inSMMC-LTNMcells administeredcholesterol-conjugatedRIG-I siRNA for 72 hr and then treatedwith IFN-aas indicated.
(C) Shown is the induced ISG expression in wild-type or RIG-I-deficient (RIG-I KO) hepatocytes stimulated with 1,000 U/ml recombinant mouse IFN-a as
indicated.
(D) Shown is the induced ISG expression in DEN-induced HCC tissues of wild-type or RIG-I-deficient (RIG-I KO) mice followed by IFN-a stimulation.
(E) Shown is the induced ISG expression in control or RIG-I stably overexpressed SMMC-7721 cells stimulated with IFN-a for the indicated time.
Data are shown as mean ± SD (n = 4) of one representative experiment. Similar results were obtained in three independent experiments. **p < 0.01.
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RIG-I in HCC Carcinogenesis and IFN-a Therapywe found that the RIG-I CARD domain directly binds the SH2-TA
domain of STAT1. As the CARD domain is known to activate
downstream RIG-I antiviral signaling upon RIG-I activation, its58 Cancer Cell 25, 49–63, January 13, 2014 ª2014 Elsevier Inc.interaction with STAT1 suggests that RIG-I may also function
as an important intracellular regulator to modulate other
signaling pathways. This hypothesis needs further testing and
Figure 5. RIG-I Amplifies the IFN-JAK-STAT Pathway in HCC by Promoting STAT1 Activation
(A) Shown are STAT1 phosphorylation (left) and nuclear translocation (right) determined by western blot in HCC cell lines transfected with RIG-I siRNA and
stimulated with IFN-a, b-actin as internal control, and Lamin A/C as nuclear marker and internal control.
(B) Shown is the confirmation of (A) determined in wild-type and RIG-I-deficient (RIG-I KO) hepatocytes.
(C) Shown is the endogenous interaction of STAT1 and RIG-I determined by co-IP in HCC cell lines. The left panel shows the detected STAT1 and phosphorylated
STAT1 in the precipitates of RIG-I. The right panel shows the detected RIG-I in the precipitates of STAT1. IB, immunoblot.
(legend continued on next page)
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tion receptors in the regulation of cell signaling. Moreover, it is
known that RIG-I antiviral signaling induces the production of
type I IFN, which activates the downstream JAK-STAT pathway
to induce ISG expression (Takeuchi and Akira, 2010). Here we
find that the ISG RIG-I can amplify IFN-a effector signaling. It
will be interesting to study the crosstalk between the RIG-I and
IFN downstream pathways, especially the regulation of IFN
downstream signaling by molecules in the RIG-I pathway.
Molecular profiling and identification of diagnostic and
prognostic biomarkers for HCC patients have attracted much
attention (Mı´nguez and Lachenmayer, 2011; Budhu et al.,
2006). Deregulated expression of both coding genes and non-
coding RNAs in HCC has been suggested to have considerable
potential in predicting the prognosis of HCC patients (Hoshida
et al., 2008, 2010). We report here that RIG-I expression in
HCC tissues significantly correlates with patient survival, sug-
gesting a potential molecule with prognostic value. In combina-
tion with previous reports, simultaneous analysis of multiple
genes may also prove more accurate in predicting HCC prog-
nosis. A previous report also showed that patients with reduced
miR-26 expression in HCC had a favorable response to adjuvant
IFN-a therapy (Ji et al., 2009). It would be interesting to investi-
gate whether potential correlations exist between miR-26 and
RIG-I expression in HCC and whether combined detection of
miR-26 and RIG-I expression may be more precise in identifying
responders to IFN-a therapy.
The detailed mechanisms of RIG-I in preventing HCC carcino-
genesis need to be further investigated. We postulate that host
IFN-amay be important in the prevention of HCC carcinogenesis
and that low expression of RIG-I may impair cellular response to
IFN-a, promoting HCC carcinogenesis. Moreover, as STAT1
activation has been shown to suppress HCC development
(Chen et al., 2013a; Zhu et al., 2010), the promotion of STAT1
activation by RIG-I may also have tumor-suppressive roles.
There may also be other ISGs modulating IFN-a responses,
and future work will be needed to fully reveal the roles of ISGs
in the regulation of IFN-a effector signaling and antitumor
responses.
EXPERIMENTAL PROCEDURES
Clinical Specimens
This study involved four independent cohorts of HCC patients. They were
cohort 1, 152 patients from Sun Yat-sen University (Guangzhou, China); cohort
2, 140 patients from the Affiliated Tumor Hospital of Guangxi Medical Univer-
sity (Nanning, China); cohort 3, 76 HCC patients from the University of Hong
Kong (Hong Kong, China); and cohort 4, 75 HCC patients from Zhongshan
Hospital (Shanghai, China). Cohorts 3 and 4 were from two independent clin-(D) Shown is the endogenous interaction of STAT1 and SHP1 as determined by c
IFN-a as indicated.
(E) Wild-type orSHP1-deficient (SHP1KO)mice were injected with cholesterol-co
followed by peritoneal injection of 5 3 106 U/kg IFN-a was detected by qRT-PC
(F and G) Wild-type or fragments of RIG-I (F, left), SHP1 (F, right), and STAT1 (G) w
V5-tagged STAT1 (F) and association of Flag-tagged STAT1 with V5-tagged RIG
CTD, C-terminal domain.
(H) Shown is the in vitro dephosphorylation assay of precipitated STAT1 protein co
both. Phosphorylated STAT1 and tyrosine were detected by western blot. STAT
Experimental data are shown as mean ± SD (n = 4) or photographs of one re
experiments. **p < 0.01. See also Figure S3.
60 Cancer Cell 25, 49–63, January 13, 2014 ª2014 Elsevier Inc.ical trials of adjuvant IFN-a therapy for HCC patients. Cohort 3 included 39
HCC patients in the control group and 37 in the IFN-a-treated group, and
was a subset of patients as previously reported (Lo et al., 2007). Cohort 4
included 35 HCC patients in the control group and 40 in the IFN-a-treated
group, and was a subset of patients as previously reported (Sun et al.,
2006). These patients had first undergone radical resection of HCC, which
was made into tissue microarray slides, and then were randomly assigned to
control or IFN-a-treated groups, and both groups were strictly followed as
described previously (Sun et al., 2006; Lo et al., 2007). Normal human liver
tissues were obtained from distal normal liver tissue of liver hemangioma
patients. All samples were collected with written informed consent from the
patients and were approved by the institutional review board at each study
center.
Reagents
Antibodies specific to phospho-STAT1 (9171), STAT1 (9172), SHP1 (3759),
b-actin (4970), and horseradish peroxidase-coupled secondary antibodies
(7074 and 7076) were from Cell Signaling Technology. Antibodies specific to
Lamin A/C (sc-56140) were from Santa Cruz Biotechnology. Antibodies
specific to Flag tag (F1804) were from Sigma. Antibodies specific to V5 tag
(ab9116) and hepatocyte-specific antigen (ab75677) were from Abcam.
Cholesterol-conjugated RIG-I siRNA for in vivo RNA interference and its nega-
tive control were from RiboBio (Hou et al., 2011). DEN (N0258) was from
Sigma.
Tissue Microarray and Immunohistochemistry
Protein levels of RIG-I expression in tissues were determined using tissue
microarray (TMA). TMAs were assembled using a manual tissue puncher.
The different samples were punched out from selected regions of tissues
and assembled into a new paraffin block. Tissue cores were 2 mm in diameter,
and the length ranged from 4 to 6 mm. TMAs were sectioned (5 mm) and
stained with H&E to verify histology. The immunohistochemistry stainings
were performed on 5 mm sections. The sections were placed on polylysine-
coated slides, deparaffinized in xylene, rehydrated through graded ethanol,
quenched for endogenous peroxidase activity in 3% hydrogen peroxide,
and processed for antigen retrieval by microwave heating for 7 min in
10 mM citrate buffer (pH 6.0). The primary anti-RIG-I antibody (ab45428;
Abcam) was diluted 1:200 in PBS containing 1% BSA and incubated at 4C
overnight. The next day, immunostaining was performed using the Dako
ChemMate EnVision Detection Kit peroxidase/diaminobenzidine (DAB) rab-
bit/mouse, which resulted in a brown-colored precipitate at the antigen site.
Subsequently, sections were counterstained with hematoxylin (Zymed Labo-
ratories), mounted in nonaqueous mounting medium, and coverslipped.
Pictures were acquired using a HistoFAXS system, and mean DAB staining in-
tensity was calculated using HistoQuest software (both from TissueGnostics)
(Puhr et al., 2009), which represents the quantitative protein expression level
of RIG-I. In each tissue, the average DAB staining intensity of the selected
two cores represents the quantitative protein expression level of RIG-I in these
tissues.
In Vivo Assay
All animal experiments were undertaken in accordance with the National Insti-
tute of Health Guide for the Care and Use of Laboratory Animals, with the
approval of the Scientific Investigation Board of the Second Military Medical
University, Shanghai, China. All animals were housed in a virus-free facilityo-IP in liver tissues of wild-type and RIG-I-deficient (RIG-I KO) mice treated by
njugated control RNA orRIG-I siRNA, and then TRAIL expression in liver tissues
R.
ere constructed as indicated. Association of Flag-tagged RIG-I and SHP1 with
-I and SHP1 (G) were determined using co-IP in the transfected HEK293 cells.
incubated with the purified RIG-I N-terminal CARD domain, full-length SHP1, or
1 was detected as an input control.
presentative experiment. Similar results were obtained in three independent
Figure 6. RIG-I Deficiency Promotes HCC Carcinogenesis and Hepatic RIG-I Expression Is Lower in Men Than in Women
(A) RIG-I expression in liver tissues of wild-type and RIG-I-deficient (RIG-I KO) mice was detected by western blot.
(B) Shown are liver tumor incidence (left; Fisher’s exact test), tumor number per animal (center; unpaired t test), and maximal tumor diameter per animal (right;
unpaired t test) of the DEN-induced HCC model in wild-type and RIG-I-deficient (RIG-I KO) mice. Fifty mice were included in each group. Experimental data are
shown as mean ± SD (n = 50) of one representative experiment. Similar results were obtained in four independent experiments. **p < 0.01.
(C) Gross appearances of representative livers with tumors in (B).
(legend continued on next page)
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A human HCC-bearing nude mice model (SMMC-LTNM) was prepared by
transplanting histologically intact fresh humanHCC tissues to form subcutane-
ous transplantation tumors in nude mice and then continuously maintained
with subcutaneous passage (Hou et al., 2011). For delivery of cholesterol-
conjugated RNA, 10 nmol RNA in 0.1 ml saline buffer was locally injected
into the tumor mass once every 3 days (Hou et al., 2011). Recombinant IFN-
a-2b (5 3 106 U/kg; Kaiyinyisheng) was injected subcutaneously daily (Wang
et al., 2000). Tumor size was measured and serum AFP was detected as
described previously (Hou et al., 2011). For the SMMC-7721 xenograft model,
1 3 107 cells were subcutaneously injected and inoculated in nude mice and
then treated with IFN-a and the effectiveness was measured. RIG-I-deficient
mice were generated as described previously (Wang et al., 2007; Zhang
et al., 2008; Hou et al., 2009). SHP1-deficient mice were described previously
(An et al., 2008). Wild-type littermates were used as control mice. For chemical
induction of hepatocarcinogenesis, mice at postnatal day 15 were injected
intraperitoneally with 25 mg/kg DEN and then maintained on regular chow
food as reported (Naugler et al., 2007). Livers and tumors were photographed
and harvested for analysis 8 months after the initial injection. Recombinant
mouse IFN-a (5 3 106 U/kg; 130-093-130; Miltenyi Biotec) was used for sub-
cutaneous injection and stimulation.
Statistical Analysis
Data are presented as mean ± SD. Statistical comparisons between experi-
mental groups were analyzed by unpaired Student’s t test, and a two-tailed
p < 0.05 was taken to indicate statistical significance. For analyzing the clinical
variables in the HCC cohorts, c2 test and one-way ANOVA in SPSS 17.0 were
used and the p values are indicated. Kaplan-Meier survival analysis was used
to compare HCC patient survival based on dichotomized RIG-I expression
using SPSS 17.0 with statistical p values generated by the log-rank test.
Cox proportional hazards regression analyses were used to analyze the effect
of clinical variables on patient survival using SPSS 17.0. A univariate test was
used to examine the influence of each clinical variable on survival. A multivar-
iate analysis was performed considering clinical variables from the univariate
analysis that were significantly associated with survival, with significance set
at p < 0.05. The p values and hazard ratios are indicated.
For RNA isolation and real-time qRT-PCR analysis, microarray analysis,
cell lines and transfection, RNA interference, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, apoptosis assay, bisulfate
sequencing, ChIP assay, dephosphorylation assay, confocal microscopy,
tumorigenicity assay, immunoprecipitation, and western blot, please see Sup-
plemental Experimental Procedures.
ACCESSION NUMBERS
The cDNA microarray data have been deposited in the Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo) under accession num-
ber GSE34674.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and nine tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.11.011.(D) The survival curves of wild-type and RIG-I-deficient (RIG-I KO) mice injected
data are shown as Kaplan-Meier survival curves of one representative experim
independent experiments.
(E) Shown are male versus female ratios of liver tumor incidence, tumor number
shown as mean ± SD (n = 4) of four independent experiments. *p < 0.05; **p < 0
(F and G) Shown is RIG-I expression in nontumor liver tissues from female andmal
ofmen andwomen (G; left, mRNA level; right, protein level). The horizontal lines in t
whiskers represent the 2.5th and 97.5th percentiles. The p values shown were c
(H) Shown is RIG-I expression in normal liver of male and female mice as indicat
Similar results were obtained in three independent experiments. *p < 0.05; **p <
See also Figure S4 and Table S9.
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